검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 18F-FLT |
Overview Company | Angiochem Inc |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Brain Metastases |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.. Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imaging, and many have unusual immune-related adverse events that cannot be predicte… |
Clinical Primary efficacy | ORR 71% |
Clinical ORR | 71% |
Clinical Result source | ClinicalTrials.gov NCT01621906 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | 18F-FLT |
Overview Company | Angiochem Inc |
Overview Modality | ANTIBODY |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Brain Metastases |
Overview Phase | PHASE_2 |
Overview Status | ACTIVE |
MoA Biomarker | Biomarker of Tumor Cell Proliferation, Detected Differential Response to Various Cyclin-Dependent Kinase (CDK |
PK/PD Species | Mouse, Rat |
PK/PD Animal (cat.) | Mouse, Rat, In vitro |
PK/PD Experiment | Pharmacodynamic |
Toxicology Species | Mouse, Rat |
Toxicology Animal (cat.) | Mouse, Rat, In vitro |
Toxicology Major finding | FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab.. Immunotherapy has demonstrated remarkable success in treating different cancers. Nonetheless, a large number of patients do not respond, many respond without immediate changes detectable with conventional imaging, and many have unusual immune-related adverse events that cannot be predicte… |
Clinical Primary efficacy | ORR 71% |
Clinical ORR | 71% |
Clinical Result source | ClinicalTrials.gov NCT01621906 |
Clinical Data Tier / Score | A · 55 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교